Freezing semen doubles the chances of fatherhood for men after treatment for Hodgkin lymphoma

December 17, 2013

Men with Hodgkin lymphoma who want to become fathers after their cancer treatment have greatly increased chances of doing so if they have frozen and stored semen samples beforehand, according to research published online today (Wednesday) in Europe's leading reproductive medicine journal Human Reproduction [1].

In the first study to investigate the impact on fatherhood of freezing semen prior to cancer treatment, researchers questioned 902 male survivors of Hodgkin lymphoma in five European countries (France, Belgium, The Netherlands, Italy and Switzerland) and found that among the 334 who wanted to have children, the availability of frozen semen doubled their chances of doing so when compared with men who had not frozen their semen.

Dr Marleen van der Kaaij (MD), who carried out the work while she was a PhD student at the University Medical Centre in Groningen (The Netherlands) [2], said: "Our study shows that cryopreservation of semen before cancer treatment has a large impact: one in five children born after Hodgkin lymphoma treatment was born using cryopreserved semen. Among survivors wishing to become a father after treatment, availability of cryopreserved semen doubled the odds of successful fatherhood."

She said the findings emphasise the importance of semen cryopreservation. "Cryopreservation should always be offered to all male patients about to undergo cancer treatment - even in situations where treatment should start urgently or where first-line treatment is not very toxic to fertility. Clinicians should realise the enormous impact of this cheap and simple procedure."

Until now, little has been known about the proportion of cancer patients who freeze semen before their treatment; there have been a few studies from single fertility centres with limited follow-up of the patients. The current study was based on 3399 male Hodgkin lymphoma patients from 13 European countries who had been included in eight, multi-centre, randomised clinical trials of cancer treatments between 1974 and 2004, run by the European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Étude des Lymphomes de L'Adulte (GELA).

In 2008 the researchers sent questionnaires to 1849 survivors in five of the countries and received 902 replies containing the information they needed. The men ranged in age from 15-69, with a median average age of 31. A total of 363 out of the 902 (40%) men had had their semen frozen before starting cancer treatment. Out of these 363 men, 78 (21%) used it following their treatment.

Among the 334 men who wanted to have children after their treatment, 206 (62%) became fathers without any medical assistance, but 128 (38%) were unable to achieve an unassisted spontaneous conception and needed medical help. Frozen semen was available for 99 (77%) of these 128 men; of these 99 men, 78 used the frozen semen and 48 succeeded in conceiving on or more children. Of the remaining 30 men, 27 failed to conceive any children and three had a child spontaneously without the frozen sperm.

Dr van der Kaaij said: "Twenty-three percent of men unable to conceive spontaneously did not have cryopreserved semen available and could not become fathers. Whereas, among men who did use cryopreserved semen we found a success rate of 62% and several men were still in the process of fertility treatment at the time of the survey. This underlines the importance of making available information and access to cryopreservation facilities for cancer patients."

Treatments for Hodgkin lymphoma have changed over the period of the study and also depend on how advanced the disease is. Both radiotherapy and chemotherapy can be used, but whereas radiotherapy can be targeted to a particular area, chemotherapy is a systemic treatment affecting the whole body. The standard chemotherapy for the disease may use alkylating agents - drugs that damage the DNA of cells - or non-alkylating agents. Alkylating chemotherapy is used widely for more advanced disease and can cause long-term infertility in over 80% of men. However, chemotherapy regimes that do not use alkylating agents are likely to cause infertility in less than 10% of men, and these regimes are more likely to be used for early stage disease.

The researchers found that men treated with chemotherapy were four times more likely to freeze their semen, and twice as likely if they were receiving a second-line treatment for progression or relapse, which would be more likely to be alkylating therapy. Better educated men were 60% more likely to freeze their semen, and men aged older than 30 were less likely to freeze semen than men younger than 30. Men treated after 1994 were more than ten times more likely to freeze semen than those treated between 1974-1983, and men treated between 1984-1993 were four times more likely than men treated before 1984.

"There are a number of probable reasons why men were more likely to cryopreserve semen after 1994," said Dr van der Kaaij. "These include the prevalence of semen cryopreservation facilities and awareness and knowledge of the possibilities, which have steadily increased since the 1970s; fertility preservation techniques really began to become part of regular medical procedures from the 1990s onwards; doctors have grown to be more comfortable with suggesting semen cryopreservation to patients; knowledge on the potentially devastating effects of cancer treatment on fertility has increased from the mid-1980s onwards; and attitudes amongst doctors have changed from being strictly oriented towards survival to including quality of life and other more patient-centred issues."

She concluded: "This paper is part of a large project on long-term treatment toxicity experienced by Hodgkin lymphoma patients. Further projects will focus on other aspects, such as adverse effects on the heart, secondary malignancies and chronic fatigue. We are also planning to publish data on sexuality and relationships."
[1] "Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study", by M.A.E. van der Kaaij et al for the European Organisation for Research and Treatment of Cancer Lymphoma Group and the Groupe d'Étude des Lymphomes de L'Adulte. Human Reproduction journal. doi:10.1093/humrep/det430

[2] Dr van der Kaaij is now a resident in internal medicine at the VU University Medical Centre, Amsterdam (The Netherlands).

European Society of Human Reproduction and Embryology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to